Kenneth R. Chapman

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman et al. · New England Journal of Medicine · 2016 · 870 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Shawn D. Aaron, Katherine L. Vandemheen, Dean Fergusson et al. · PubMed · 2007 · 654 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen et al. · The Lancet · 2015 · 504 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Marked Flow-Dependence of Exhaled Nitric Oxide Using a New Technique to Exclude Nasal Nitric Oxide

Philip E. Silkoff, Patricia McClean, Arthur S. Slutsky et al. · American Journal of Respiratory and Critical Care Medicine · 1997 · 470 citations

Life Sciences, Clinical Sciences, Physiology +16

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

Nicola A. Hanania, Phillip E. Korenblat, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2016 · 466 citations

Medicine, Internal Medicine, Pharmacology +10